Q&A: Amgen's Alex Parker on Next-Gen Sequencing to Study Patient Response in Clinical Trials

Parker, a principal scientist in Amgen's Molecular Sciences group, spoke with In Sequence about the role of next-generation sequencing in his work, and where he sees a place for emerging sequencing technologies at Amgen.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories